"Advancing the discovery and translation of new knowledge about cancer risk and prevention in the laboratory, the clinic and the community"
A Message from the Vice President
I am delighted to provide you with our third annual report detailing the progress we've made towards accomplishing the founding goals of the Duncan Family Institute. In the three years since its inception, we have made considerable strides in developing and establishing research programs and resources aimed at gaining a better understanding of cancer in its earliest stages, providing safer and more effective prevention strategies and advancing cancer risk assessment in both the clinic and the population overall. Just as importantly, we've done this together as a leadership team focused on fostering new discoveries and seeing them transformed into tools to benefit everyone at risk for, or living with, a diagnosis of cancer. Therefore, the DFI enjoys widespread support by our faculty who are deeply grateful for the opportunities it provides to transform our research and clinical practice. Our Seed-funding Research Program has been expanded to faculty throughout MD Anderson, resulting in awards to eight of 27 investigators who applied for funding. We collaborated with the Survivorship Research Working Group to contribute support to five awards from a pool of 35 proposals, a large number which signals expanding research on issues important to this rapidly growing patient population.
Additionally, the Institute has enhanced its overall research infrastructure with the funding of the Clinical Cancer Prevention (CCP) Research Core and its High Risk Breast Cancer Cohort. The CCP will work in conjunction with four other resources-the Personalized Risk Prediction Program (PRPP) , the e-Health Technology core, the Mexican-American Cohort Study, and the Center for Community, Implementation, and Dissemination Research (CCIDR) -to strengthen the quality and impact of cancer prevention research across the continuum from basic through translational to clinical and population-based science. Details of this new core, as well as the latest findings from research supported by the four initiatives, can be found in the Research Resources section. In closing, I sincerely thank all those who are affiliated with the Duncan Family Institute for their hard work and support of this past year's accomplishments. And I extend my deepest appreciation to the Duncan family and to all of our new and sustaining donors, whose generosity and recognition of the importance of cancer prevention made possible this Institute and its many advances in 2011. Investing in promising new research directions and in the expansion and integration of MD Anderson's cancer prevention program, the Institute in 2011:
• Awarded 13 seed-funding research grants to help researchers develop or expand their studies; • Funded several studies on high-priority topics, such as tobacco use, personalized prevention and treatment, and precancerous conditions; • Invested in infrastructure to help researchers be more successful and compete for outside funding; • Worked to bring research discoveries into the real world to help people fight cancer; • Awarded one new junior faculty fellowship;
• Sponsored scientific lectures about topics in cancer prevention and treatment; and • Engaged in strategic planning to set priorities for research and services.
The Institute will continue to grow and expand in the coming year. We are confident that the investments and collaborations made in Fiscal Year (FY) 2011 strategically position us to implement those plans and reach out to form new partnerships as we work to make the Institute a center for high-impact cancer prevention research. 
RESEARCH PROGRAMS -STUDIES TO UNDERSTAND AND REDUCE CANCER RISK
The Duncan Family Institute currently invests 40% of its funding into two research programs, a Seed-funding program and a Strategic Research Initiatives program.
The Seed-funding Program provides financial support to innovative investigators early in the development of their ideas. The awards assist them in gathering the data needed to compete successfully for external funding. In 2011, the Institute began partnering with the Survivorship Research Group and provided seed funds to a number of projects addressing quality-of-life issues in this area. Survivorship Research focuses on the health and life of a person with a history of cancer beyond the acute diagnosis and treatment phase. It seeks both to prevent and control adverse cancer diagnosis and treatment-related outcomes. With improvements in cancer treatment, there will be an increasing need to address the issues survivors face. Currently, there are an estimated 13 million U.S. cancer survivors with long-term needs. The Institute aims to make critical contributions to this developing area of research. In the future, we will continue to form new collaborations that will assist us in advancing and addressing the issues in survivorship research at both the state and national levels. 
AN ENGINE FOR DISCOVERY -SEED-FUNDING RESEARCH PROGRAM
The Duncan Family Institute provides individual seed-funding grants to help investigators take the first steps to advance promising research ideas and compete successfully for grants from outside agencies. This helps leverage our resources to have a greater impact on discovery of new ways to prevent and treat cancer.
In FY11, we awarded funds to eight proposed projects through a competitive peer-review process. Also, through a new collaboration with MD Anderson's Survivorship Research Group, the Institute contributed to five projects that will help survivors cope with the many complex issues beyond diagnosis, such as quality-oflife and prevention of secondary cancers.
The six investigators who received awards in prior years are progressing well, and two have been awarded outside funding. Others are preparing submissions or awaiting reviews.
Scientists who receive seed grant awards are working in diverse areas to help fight cancer, including studies to:
• Discover new ways to prevent cancer, including lifestyle changes and personalized medicine;
• Study why some groups get cancer more often than the general public;
• Explore novel ways to treat cancer, including less-toxic chemotherapy and gene-based therapies; and • Improve quality of life for cancer survivors in areas such as fatigue, loss of sexual desire and changed appearance.
Here are brief descriptions of the projects which received seed funding last year, as well as progress updates for those awarded previously.
Identifying Neurocognitive Risk Markers that Differentiate Smokers from Never-Smokers and Ex-Smokers Jason Robinson, Ph.D., Assistant Professor, Department of Behavioral Science
Even though most smokers know smoking is unhealthy and want to quit, few do. Only 6 percent of those who make a serious cessation attempt are not smoking a year later. Like other drugs of abuse, smoking alters the brain after repeated use, making it difficult to quit permanently. The team will examine whether brain markers found in smokers also exist in never-smokers and ex-smokers. This will help identify non-smokers at risk of smoking and ex-smokers who may resume the habit.
Role of PPAR-delta Overexpression in Colonic Tumorgenesis
Imad Shureiqi, M.D., M
.S., Associate Professor, Department of Clinical Cancer Prevention
This discovery project will enhance our understanding of the role of a certain nuclear receptor in colon cancer. A seed grant last year helped us discover that too much of the receptor can promote cancer in mice. Now, we will continue our research with a larger study that will lead to preclinical testing of a drug to prevent colon cancer in people at high risk. This seed grant was a contributing factor to securing an NCI-funded R01 grant.
Integrative Genomic Analysis of Actinic Keratoses: Using Inter-lesional and Cross Species Analysis to Predict Progression to Cutaneous Squamous Cell Carcinoma Kenneth Tsai, M.D., Ph.D., Assistant Professor, Department of Dermatology
Three million people in the United States are diagnosed with skin cancer each year, making it the most common cancer. Cutaneous squamous cell carcinoma, the second most common skin cancer, begins with sun damage that progresses to actinic keratosis (AK, the most common precancerous lesion) and then to cancer. The high incidence of AK presents a vast opportunity for skin cancer prevention, and Dr. Tsai's studies to find genetic alterations that result in its formation will help design better treatment and prevention methods.
High-throughput Search for a Combination Cancer Preventive Treatment Ivan Uray, M.D., Ph.D., Assistant Professor, Department of Clinical Cancer Prevention
The two most important requirements for acceptable cancer prevention drugs are high effectiveness and low toxicity. This research aims to find drug combinations that achieve both aims. At the same time, we will examine new ways to combine cancer prevention drugs that reduce the effective dose while achieving the same or even better results. Reaching these goals may have a tremendous impact on the acceptance of drugs to prevent cancer. Although the five-year survival rate for breast cancer is as high as 90%, more than half of women have problems with sexual function, particularly if they had chemotherapy. We think chemotherapy damages parts of the brain that are necessary for emotion, contributing to loss of desire for sex. We are using functional magnetic resonance imaging (fMRI) to measure brain activity, which we hope will lead to effective remedies. Peutz-Jeghers Syndrome is a genetic disorder that puts people at high risk for benign polyps in the stomach, small intestine and colon, as well as various types of cancer. We are investigating whether niclosamide, which inhibits the mTOR pathway, prevents polyps in mice. Since this pathway is active in many cancers, the findings could impact prevention and treatment of other diseases. During the first year of this project, Dr. Wei gathered the data needed to earn an NCI grant to support further study. Xiangwei Wu, Ph.D., Associate Professor, Department of Head and Neck Surgery -Research Pancreatic cancer is often diagnosed at an advanced stage and has a poor prognosis. Mutations of the K-ras gene are possibly the single most common abnormality in this cancer. In this study, we are developing a method to specifically abolish K-rashyphenexpressing cells, with the goal of devising a personalized approach to pancreatic cancer prevention and treatment.
A Brain

Chemoprevention of Pancreatic Cancer by Induction of Synthetic Lethality in Mutant K-ras Cells
Preclinical Chemoprevention of Esophageal Adenocarcinoma Xiaochun Xu, M.D., Ph.D., Associate Professor, Department of Clinical Cancer Prevention
Esophageal cancer is more prevalent in people with frequent gastroesophageal reflux (GERD), which may result in a precancerous condition called Barrett's esophagus. This study will show that a combination of chemopreventive agents can prevent the growth of esophageal cancer cells. Last year, the team's progress enabled development of two larger studies of prevention methods for people with Barrett's esophagus.
Predicting the Risk of Developing Lung Cancer: A Multigenic Statistical Approach to MicroRNA Yuanqing Ye, Ph.D., Assistant Professor, Department of Epidemiology
There is substantial evidence that lung cancer's development is driven by interactions between carcinogens in tobacco and genetic traits. Through this study we are identifying variants in certain genes associated with lung cancer. Last year, Dr. Ye assessed gene links in 1,135 lung cancer cases, and this year, the team will gather data for a larger multi-year study, which may shed light on the causes and prevention of lung cancer.
INVESTMENT IN NOVEL AND HIGH PRIORITY RESEARCH DIRECTIONS -DUNCAN FAMILY INSTITUTE STRATEGIC RESEARCH INITIATIVES
The Strategic Research Initiative program focuses expertise and resources on promising new and high-priority cancer prevention research areas. In FY11, we:
• Cancer often is already in an advanced stage when it is diagnosed, and treatment with chemotherapy and radiotherapy often causes severe side-effects with disappointing results. The best hope of improving this cycle is finding cancer early, or better yet, preventing it from developing in the first place.
Most epithelial cancers, which begin in the cells that line the surfaces and cavities of the body's organs, originate as premalignant lesions. The progression to cancer may take many years, giving us a window for potential intervention. However, we have not yet learned which people with premalignant lesions will go on to develop cancer or exactly how to halt the process.
Through the Premalignant Genome Atlas Program, we are studying premalignant lesions intensely to identify the changes that occur when they become cancer, hopefully leading to development of a tool we can use to predict which patients are most at risk. We can then draw upon our findings to personalize cancer prevention strategies.
Our ongoing goals were set when the program began in 2009. They are to:
• Establish a collection of tissues and data for research purposes;
• Assemble a group of patients with premalignant lesions and follow them over the long term; and • Perform molecular profiling of normal, premalignant and cancer tissues to identify factors that may predict progression to cancer.
This year, we made great strides toward accomplishing our goals by continuing to recruit study participants and collecting blood and tissue samples. We continue to collaborate with Jaffer Ajani, M.D., on Barrett's esophagus and Scott Lippman, M.D., on oral premalignant lesions. Below are examples of our FY11 research accomplishments.
Colon Polyp Study
This study is the first to show that a certain type of RNA can make a difference in whether a person develops benign polyps and whether those polyps develop into colorectal cancer. These exciting results have potential as the foundation for a non-invasive test to determine risk. Moving forward, the research sets the stage for a larger study to validate the results and, ultimately, possible ways to predict and prevent progression of polyps to cancer.
Barrett's Esophagus and Esophageal Cancer
In the first of two related studies, researchers examined 119 tissue samples to find the role of a certain type of RNA in progression from the precancerous condition Barrett's Esophagus to esophageal cancer. This led to a larger study to test findings and identify biomarkers to predict which people with Barrett's esophagus are likely to develop esophageal cancer. Scientists identified several genes to study further, and they are conducting a larger study to confirm their findings.
Looking Toward the Future
Plans for FY12 include expansion of the leadership team to add Lopa Mishra, M.D., professor and chair of the Department of Gastroenterology, Hepatology and Nutrition. Dr. Mishra will further engage physicians who perform endoscopies in the next phases of the program, which focus on collection and analysis of precancerous colorectal tissues. The program will continue to focus on oral premalignant leukeplasia, Barrett's esophagus and colon polyps, with ongoing emphasis on genetic profiling. The long-term goal is to develop novel tools to better predict which patients are at high risk for progression from normal to premalignancy, and from premalignancy to cancer. Minimum Amount of Physical Activity for Reduced Mortality & Extended Life Expectancy Wen CP, et al. Lancet Oct 1; 378(9798):1244 378(9798): -53, 2011 We still do not know exactly why some people who use tobacco do not get cancer and others do; nor do we fully understand why some people can easily stop using tobacco and others have great difficulty in doing so. Building on MD Anderson's strength as a leader in tobacco research, this developing program reaches across disciplines to understand the many issues associated with tobacco as a risk factor for cancer. Scientists from all areas within the Division of Cancer Prevention are developing studies to:
• Understand the basic science, genetic and molecular factors of tobacco use;
• Employ cutting-edge imaging techniques to study what happens in the brains of smokers; and • Address differences in tobacco use by certain subgroups.
Examples of progress in this area include a collaborative study between Lorraine Reitzel, Ph.D., Department of Health Disparities Research, and Carol Etzel, Ph.D., Department of Epidemiology, to study the impact of menthol cigarettes on both tobacco addiction and ability to quit smoking.
In addition, researchers have developed a major new program, Tobacco TIPS (Translation Into Practice Systems), for which they are submitting an application for funding to the Cancer Prevention and Research Institute of Texas. This proposed $11.5 million collaboration with the University of Texas (UT) School of Public Health aims to increase the reach of tobacco cessation treatments-including one developed by Jenny IrvinVidrine, Ph.D., Department of Health Disparities Research-among health care systems, social service agencies and providers who focus on the underserved.
Center for Translational and Public Health Genomics Director: Xifeng Wu, M.D., Ph.D., Professor and Chair, Department of Epidemiology
With the rapid development of new technologies that generate molecular information at an unprecedented pace, MD Anderson scientists are poised to make major breakthroughs in personalized cancer medicine. Streamlined data and comprehensive biological resources are essential to this progress.
The new Center for Translational and Public Health Genomics (CTPHG) is leveraging MD Anderson's large patient population and well-established foundation of research to provide support for investigators across the institution to accelerate progress in preventing, diagnosing and treating cancer.
A major initiative of the center includes the MD Anderson Cancer Patient Cohort, comprising an institutional Blood Specimen Research Resource and data collection process for newly diagnosed patients. Operating under the direction of Drs. Xifeng Wu and Stanley Hamilton, the cohort is a tremendous resource for investigators. Its potential is indicated by the collection of biosamples from more than 12,000 newly registered patients in just nine months (as of August , 2011), and a recently submitted $10 million National Institutes of Health grant aims to provide outside funding for expansion of this resource. Importantly, the initiative also provides every newly registered patient an opportunity to participate in clinical research aimed at developing better approaches for future generations.
The CTPHG has a state-of-the-art facility dedicated to the analysis of DNA. Instruments within this facility allow us to use cutting-edge approaches to study patients' genomes.
Aside from establishing patient cohorts and providing access to state-of-the-art genome sequencing equipment, the center's success in building collections of patient specimens and data has prompted the establishment of departmental processes for making sure these precious resources are properly used. These new processes are serving as a "Best Practices" guideline for the entire division. The practices will steer investigators through the complexities of accessing scarce research materials, an increasingly important task as they work to advance prevention research in this genomic era.
The center stimulates the intellectual environment for multidisciplinary interaction through a lectures series which has included noted scientists such as 
RESEARCH RESOURCES -PROVIDING CRITICAL INFRASTRUCTURE TO ADVANCE CANCER PREVENTION SCIENCE
For research to move forward, scientists must have advanced scientific technologies, biological samples, data and expertise. These essential infrastructure components often are not funded through grants and other sources, but they are necessary for researchers to compete successfully for external funding from the National Institutes of Health (NIH), National Cancer Institute (NCI) and other agencies.
After careful consideration, the Duncan Family Institute invested 40 percent of its budget to support five research resources to help scientists be more competitive:
• Personalized Risk Prediction Program;
• e-Health Technologies Core;
• Mexican-American Cohort Study;
• Center for Community, Implementation, and Dissemination Research; and
During this reporting period, the Institute funded the Clinical Cancer Prevention Research Core, which supports cancer prevention research by making it stronger and more efficient.
We are pleased with the return on our investment, as the Institute's research resources contributed to 30 grant proposals totaling more than $50 million. These resources also provided core services essential to conducting 63 actively funded research studies for which total costs exceeded $72 million. Highlights, which are described in more detail in the following pages, include:
• Support for a large study led by a group of scientists at the University of Oxford and Harvard Medical School that resulted in the most detailed genetic map to date in African Americans, published in Nature;
• An e-Health study exploring the possibility of collecting behavior-related data through sensors worn by patients or positioned in their homes;
• A novel behavioral intervention for smokers, developed in collaboration with the Harris County Hospital District and Kelsey-Seybold clinics, that significantly helped minority and medically underserved populations reach services designed to help them quit smoking; and Personalized cancer prevention, screening and early diagnosis targeted to each person's unique molecular makeup is the way of the future, and scientists are getting closer to achieving this vision every day.
Researchers working with The Duncan Family Institute Personalized Risk Prediction Program (PRPP) are investigating ways to use our differences to diagnosis cancer earlier, tailor special approaches for people at high risk and advance personalized cancer medicine.
The PRPP supported proposal development for two research projects budgeted at $1.4 million. It provided services to eight funded research projects ($3.4 million in total costs) during the past year and distributed 2,500-plus biospecimen samples to support new and ongoing studies.
Examples of the high-impact activities supported through PRPP include: • Results of several projects to which the PRPP contributed specimens and data were published, as noted in the publication list at the end of the report.
Our operational achievements included:
• Collecting and banking 18,400 samples and abstracting more than 225,000 patient records to the MD Anderson Patient History Database; • Instituting a charge structure that helped us receive more than $50,000 in user fees for reinvestment in the resource; and • Establishing and posting standard operating procedures on the Personalized Risk Prediction Program website.
SampleBank -Centralized Biospecimen and Risk Factor Repository
Building on its progress, the PRPP will continue to enhance the centralized serum plasma and DNA repository, including a project to collect cancer-specific risk factor data for all participants. We will use a uniform system to process samples, state-of-the-art archiving with a well-designed laboratory information management system (LIMS), and a web-based data entry system. This will enhance the value of these materials to investigators and allow us to use new technologies in genomics and proteomics.
Looking Toward the Future
In FY12, the PRPP will transfer some of its sample collection, processing and archiving activities to the new Center for Translational and Public Health Genomics and the Clinical Cancer Prevention Research Core, both supported by the Duncan Family Institute. This will increase efficiency, allowing the PRPP to focus on supporting investigators.
In addition, PRPP resources will:
• Expand our inventory of data and biosample collection information;
• Create a centralized resource of risk prediction tools and methods;
• Facilitate access to our expertise;
• Work closely with groups throughout the institution;
• Build upon collaborations with Baylor College of Medicine and its Dan L. Duncan Cancer Center in the areas of breast, brain and bladder cancer, as well as with the joint Childhood Epidemiology Program with Texas Children's Hospital; and • Seek collaborative opportunities with other institutions when combined expertise and resources would allow investigators to ask and answer scientific questions beyond the reach of those possible in a single institution. The tools of the digital age can help us make great strides in preventing cancer. New technology can gather or distribute information to a broad audience -or the most specifically targeted subgroup. We can educate, help change behaviors, evaluate symptoms, and help patients and survivors live healthier lives.
The Duncan Family Institute's e-Health Technology resource serves as a hub for technology-enabled research and draws investigators from across MD Anderson to work together to save lives through prevention, screening, diagnosis and treatment. Last year it developed technology platforms and tools to support 17 projects integral to more than $20 million in research, including those highlighted below.
COMBAT Alexander Prokhorov, M.D., Ph.D., Professor, Behavioral Science
In this Department of Defense-funded study ($3.7 million) at Fort Hood, Texas, researchers are developing and evaluating a program to help junior enlisted Army members avoid tobacco or quit smoking. Participants watch a movie clip and play an educational video game that communicates facts about smoking and tobacco use. We have produced six 15-to 30-second video segments for the game. Planned and completed work includes filming on and off-site, editing, graphics and formatting ( Figure 5 ).
Comparative Effectiveness Research for Cancer in Texas (CERCIT) Linda Elting, Ph.D., Professor, Biostatistics
Funded by the Cancer Prevention Research Institute of Texas ($1.3 million), this consortium includes MD Anderson, the University of Texas Medical Branch, Rice University, Baylor College of Medicine and the University of Texas School of Public Health (UTSPH)-Houston. Researchers will study patterns in cancer care across the state, then communicate findings to a broad audience including national researchers and care providers, Texas policy makers, cancer patients, and the public. e-Health Technology helped the researchers develop a strong web presence to report findings along with tools to enhance effectiveness by determining precisely what information these groups want. 
Figure 6
Smart phones are increasingly used in assessment and intervention research studies to capture data from participants or to send messages. The Android platform shown is now supported by e-Health and is being used to advance an NIH-funded study on physical activity.
Cyberinfrastructure for Comparative Effective Research (CYCORE) Principal Investigator: Susan Peterson, Ph.D., Associate Professor, Behavioral Science
This two-year project ($3.8 million) creates and tests a comprehensive state-of-the-art web-based tool to gather, process, store and retrieve information. We are exploring the feasibility of collecting behaviorrelated data through sensors worn by patients or positioned in their homes, then feeding results back to researchers. We are collaborating with Calit2, one of four California Institutes for Science and Innovation, to study real-time assessment of information using mobile devices ( Figure 6 ).
Prevail: Identifying and Monitoring Barriers to Smoking Cessation in Low Socio-economic Status Populations Principal Investigators: Michael Businelle, Ph.D. and Darla Kendzor, Ph.D., Assistant Professors at UT Health Science Center School of Public Health in Dallas
This study will identify and monitor psychosocial predictors of smoking relapse in people in low socioeconomic groups in Dallas. Participants will carry smart phones for two weeks to capture response patterns in key variables (e.g., recent alcohol use, negative affect, craving, self-efficacy for quitting) that may predict relapse. e-Health helped develop the phone application, built a manager interface for desktop computers, and provided software installation, training and support.
CAMPad -an iPad Application for Complementary and Alternative Studies Principal Investigator: Michael Fisch, M.D., Chair and Professor, General Oncology
The major goals of this project are to develop and install an iPad application to help cancer patients stick with treatment regimens. e-Health will develop and install the software, secure-data storage and transfer, and provide user training and support (Figure 7 ).
Other Achievements e-Health Technology staff contributed their ideas and expertise, as well as project approach and estimates, to seven proposed research projects totaling more than $1.3 million in budgeted costs. We:
• Expanded engagement with researchers to be sure we are meeting their needs;
• Added Apple and Android platform capability;
• Negotiated a cost-effective leasing program with a major cell phone vendor; • Overhauled our website to better communicate and acquire user feedback; and • Developed a speaker series that began in Fall of 2011 to enhance understanding of new technologies for our investigators.
Looking Toward the Future
Going into our third year of operation, we plan to:
• Continue to build collaborations and capabilities;
• Develop video presentations for the e-Health website to educate about our capabilities;
• Expand collaborations with internal and external IT groups; and • Develop the intellectual environment through sponsoring e-Health speakers. (as of 8/2011) Mexican Americans are the largest and fastest-growing ethnic minority in the United States and the largest subgroup in Texas -yet they are an understudied group when it comes to cancer. The Mano a Mano (Mexican-American) Cohort Study -one of the first studies of its kind -focuses on Mexican-American households to discover information about environment, family and social support systems, economic and other resources, barriers, family history of disease and residency (Figure 8 ).
Mexican-American Cohort Study
Launched in 2001 by the Department of Epidemiology with resources from Texas Tobacco Settlement and philanthropic funds, the program was designed specifically to:
• Understand cancer-related risk factors in a population undergoing dramatic social change; • Identify risk factors to prevent cancer and reduce cancer-related disease and deaths; and • Advance the MD Anderson mission to eliminate cancer through patient care, research, prevention and education. At the end of FY11, the Cohort included more than 15,000 households and 22,000 participants. We piloted a new recruitment strategy using community enrollment sites to increase the number of interviews we can conduct and to reduce recruitment costs. Also, we continue to follow-up with participant households every six months for the first three years and then annually.
In an attempt to not only study, but improve the health of this community, several research studies targeted to understanding and reducing cancer risk in Mexican Americans were supported by the Cohort. Initially, it will focus on recruiting 400 study participants who are considered high risk.
Latinos Contra El Cancer
Biobehavioral-Smoking Profiles of Mexican Origin Youth Anna Wilkinson, Ph.D., Assistant Professor, UT Health School of Public Health -Austin Campus, Supplement to NCI K07 CA126988, ~$750,000
Last year, we reported on Dr. Wilkinson's studies to advance understanding of the influences that increase Mexican-American youth's susceptibility to tobacco and likelihood of becoming smokers. In this follow-up project, she is re-interviewing the original participants to learn about their smoking behaviors. She will use these findings to build larger, longer-term studies focused on developing more effective, culturally appropriate strategies (both school-and community-based) for promoting healthier lifestyles.
Breast Cancer Risks in Mexican-American Women Principal Investigator: Melissa Bondy, Ph.D., Professor, Department of Epidemiology
Although research has shown that non-Hispanic white women are at higher risk for cancer if they are postmenopausal and obese, that is not the case for Hispanic women. In fact, this study of more than 400 women found no connection between body mass index and breast cancer in Mexican-American women, regardless of menopausal status. Investigators believe this may be because Mexican-American women go through menopause an average of two years earlier than non-Hispanic white women, meaning they were exposed to less estrogen.
Looking Toward the Future
Our goals for next year, which are aimed at enhancing the value of this resource to researchers, the community and the Cohort participants, are to:
• Continue recruiting participants, targeting people over 40 to reflect the demographics of the MexicanAmerican population in Houston; • Contact Cohort participants who have been lost to follow-up to invite them back into the study;
• Develop new research initiatives and expand collaborations within and outside MD Anderson; and The project, now in its third year of follow-ups, launched a new study last year. Called Healthy Habits, the initiative is funded by the Houston Endowment and focuses on obesity prevention. Dr. McNeill, the project leader, was recently awarded the Rogers Award for Excellence in Prevention (Figure 11 ).
Clinical Trial Disparities
Clinical trials help move science forward and often provide the latest prevention and treatment options. However, the number of African Americans who participate in clinical trials lags far behind that of whites, despite the fact that proportionally, African Americans carry a much higher cancer burden.
CCIDR is working closely with researchers inside and outside of MD Anderson to increase awareness of barriers and help create strategies to improve participation and retention ( Figure 12 ). We are building longterm relationships with partners including:
• Harris County Hospital District;
• Windsor Village United Methodist Church;
• Community service organizations and community-based health centers, including many that are Federally Qualified Health Centers; and • MD Anderson's Comprehensive Cancer Control. 
Looking Toward the Future
In FY12, CCDIR will focus on several projects, including a tobacco cessation program that considers genetic, neuroscience and neighborhood factors. Another planned study will partner with Federally Qualified Health Centers (FQHC) to share expertise and build collaborations aimed at helping these facilities serve their lower income and underserved patient populations.
To strengthen our capabilities, we will:
• Promote awareness of the tools we offer;
• Recruit a research scientist;
• Develop a communications and promotions strategy;
• Network with leaders in community dissemination research; and • Seek extramural funds to further support our vision and goals.
Clinical Cancer Prevention Research Core
Co-directors: Powel Brown, M.D., Ph.D., Professor and Chair, Department of Clinical Cancer Prevention Therese Bevers, M.D., Professor, Department of Clinical Cancer Prevention and Medical Director, Cancer Prevention Center
The Clinical Cancer Prevention Research Core (CCPRC) provides resources to help bring cancer prevention research to patients in real-life, clinical settings ( Figure 13 ). We collaborate with investigators on many levels and help them strengthen the quality of their research, so they can have a more profound impact on saving lives.
We support studies by Clinical Cancer Prevention researchers that are ready for implementation, and we have established the High Risk Breast Cancer Cohort and Biorepository, a shared research resource for MD Anderson investigators. 
High Risk Breast Cancer Cohort and Biorepository
This project is collecting blood samples and information about breast cancer risk factors and outcomes from cancer-free patients at elevated risk of developing invasive breast cancer. It provides a ready-access resource for researchers interested in developing breast cancer research studies. This cohort is under the leadership of Dr. Therese Bevers and Abenaa Brewster, M.D., (Figure 14 ).
During this first year of operations, 605 potential participants were identified. The next step is to invite them to take part in this important program, which is providing services to two clinical trials.
Trial of Lapatinib for the Treatment of Women with DCIS Breast Cancer Powel Brown , M.D., Ph.D., Principal Investigator, Chair and Professor Clinical Cancer Prevention in collaboration with Henry Kuerer, M.D., Ph.D. co-Principal Investigator, Professor, Surgical Oncology
In this multi-institution project funded by the Breast Cancer Research Foundation, women with newly diagnosed ductal carcinoma in situ (DCIS) are treated with lapatinib or placebo for two to six weeks.
Looking Toward the Future
CCPRC's plans for next year include:
• 
EDUCATION AND EXCELLENCE
The Duncan Family Institute Executive Committee committed 10% of the Institute's budget to activities to develop future generations, support current generations and assure the quality of Institute programs. Through the joint leadership of Dr. Hawk, department chairs and center directors in the Division of Cancer Prevention and Population Sciences (Figure 15 ), the Institute plans and evaluates every initiative to ensure that each moves toward our goals of preventing cancer -and that all align with the intentions of those whose gifts make the Institute possible. Members actively promote Institute initiatives to colleagues across the campus, and, through their leadership roles, regionally and nationally to broaden the reach and collaborative opportunities of the Institute.
DEVELOPING THE NEXT GENERATIONS -DUNCAN FAMILY INSTITUTE MENTORED JUNIOR FACULTY FELLOWSHIP
These competitively awarded fellowships help promising young researchers bridge the gap between postdoctoral training and independent researcher status ( Figure 16 ). They provide mentoring and financial support for instructor-level faculty members to focus on developing their research questions, generating preliminary data and enhancing their publication record to compete successfully for peerreviewed extramural grants -an early and critical milestone on the path to research independence.
Our first two fellows, Drs. Francesco Versace and Larkin Strong, successfully moved into tenure-track faculty positions at MD Anderson, a testament to the value of this fellowship toward advancing the careers of future cancer prevention researchers. We appointed a third fellow in FY11, Jian Wang, Ph.D., instructor of epidemiology, whose research has the potential to develop personalized smoking cessation programs. The fellowship support allowed Dr. Versace ( Figure 17 ) to further strengthen his neuroimaging expertise, conduct new experiments exploring the role of brain reward sensitivity in smoking relapse and collect preliminary data which led to a funded NIH R01 grant. He is expanding his work to cancer survivorship, with the recent award of a Cancer Survivorship Research Seed Money Grant. The goal of this new project is to use neuroimaging to study reduced sexual desire in breast cancer survivors.
Larkin Strong, Ph.D., Instructor, Department of Health Disparities Research Opportunities for Cancer Prevention: Identifying Multilevel Influences of Physical Activity and Obesity in Diverse Populations
In just nine months, Dr. Strong ( Figure 18 ) worked closely with her mentor, Dr. Wetter to target her research and move toward research independence. Her efforts focus on how physical, social and cultural factors influence health behaviors and outcomes in diverse populations. For her fellowship, she developed a project to assess multi-level influences of physical activity in Mexican-American adolescents, looking at individual, interpersonal and neighborhood factors.
She also is conducting a study to examine the links between physical activity, walking and sedentary behaviors and perceptions of physical and social environments among members of an African-American church-based group. Dr. Strong is a co-investigator on the Community Networks Program "Por Nuestra Salud" and has submitted a proposal to the National Heart Lung and Blood Institute Mentored Research Scientist Development Award (K01) program for a project titled "Pathways Linking Neighborhoods and Activity Behaviors in Diverse Populations." 
Jian Wang, Ph.D., Instructor, Department of Epidemiology Risk Modeling Using Mediation Analysis and Bayesian Network Recovery with Application to Smoking Cessation Study
Dr. Wang, the newest Duncan Family Institute Fellow (Figure 19 ), is researching new statistical approaches for designing smoking cessation programs that will help identify the complex relationships among genetic variants, environmental risk factors (e.g., number of smokers in family and social context) and smoking.
Results of her studies have the potential to lead to creation of a risk model for smoking cessation that considers all of these factors. Such a model could provide insights to the development and tailoring of prevention strategies for people at risk for nicotine dependence as well as effective medications for smokers who want to quit.
Dr. Wang's long-term career goal is to become an independent researcher in behavioral and genetic statistics. The Duncan Family Institute fellowship will provide her an opportunity to integrate her knowledge of theoretical statistics, epidemiology, behavioral science and genetics through work with expert mentors on multi-disciplinary projects -an important next step toward career independence. 
INVESTING IN THE CURRENT GENERATION
PLANNING FOR EXCELLENCE AND BUILDING FOR THE FUTURE
The Duncan Family Institute worked with its Scientific Executive Committee to set research priorities and guide investments in areas of greatest promise. The Division of Cancer Prevention and Population Sciences established, managed, facilitated and promoted the Institute's initiatives. It measured and reported scientific progress and disseminated information on Institute research resources and funding opportunities.
The Institute's science is disseminated through newsletters, blog posts and via video, posted on the Institute's website and YouTube ( Figure 21 ).
The Scientific Executive Committee has defined new directions for development next year in these areas:
• Cancer survivorship research;
• Image-based screening and early detection;
• Global cancer prevention programs;
• Energy balance, integrative health services and tobacco research programs; and • Investment in research resources and cohorts, as well as critical research infrastructure for populationand community-based studies.
The following summaries highlight scientific accomplishments of Duncan Family Institute leadership and awardees-providing a snapshot of the breadth of research interests, national and international engagement, and contributions of those who are joined together to advance the science and practice of cancer prevention. Her clinical and research interests are breast cancer prevention, screening and diagnosis. She was the MD Anderson principal investigator (PI) on two national groundbreaking trials: the Breast Cancer Prevention Trial which demonstrated that tamoxifen reduces the risk of developing breast cancer by half; and the STAR trial, which showed that raloxifene has similar benefits but fewer risks. She is the institutional PI of a study of polyphenon E (an active substance of green tea) in women at increased risk for breast cancer. He has cared for women with breast cancer for more than 25 years and focused his research on signaling pathways for prevention and treatment of breast cancer. He demonstrated that drugs related to vitamin A prevent ER-negative breast cancer, and he uses genomics and proteomics to identify drugs for breast cancer prevention and treatment.
DUNCAN FAMILY INSTITUTE SCIENTIFIC LEADERS AND RESEARCHERS
Dr. Brown earned his bachelor's degree at the University of North Carolina and his medical degree and Ph.D. from New York University. He completed an internal medicine internship and residency at Duke University, a medical oncology clinical fellowship at the National Cancer Institute (NCI) and a research fellowship at the Navy Medical Oncology Branch, NCI. Dr. Cinciripini's research has explored behavioral and pharmacological treatments for nicotine dependence, nicotine titration and compensation, psychophysiological effects of nicotine during stress, individual differences in the effects of nicotine on EEG and cardiovascular activity, genetic factors, treatment outcome, and pharmacogenetic effects of antidepressants during smoking cessation. He also has studied the effects of depression, coping behavior as well as genetic factors related to nicotine dependence.
Dr. Cinciripini received several NIH, extramural and industry-sponsored research grants and is the author of more than 100 articles and book chapters. Her research is directed at understanding the genetic risks of cancer by building risk models that use epidemiologic and genetic data to characterize risk of disease and identify subgroups at highest risk. Dr. Etzel completed an NCI-funded fellowship in Cancer Prevention and is principal investigator of two NCI-sponsored grants. She studies risk factors associated with poor adjustment to alterations in body image and develops interventions to alleviate distress. Her work has received funding from ACS and NCI. She launched the Body Image Therapy Service to provide counseling to patients with head and neck and breast cancer who are having difficulty adjusting to appearance-related changes resulting from their disease and treatment. Her research is on the elimination of cancer-related health disparities in minority populations, with emphasis on understanding the influence of social and environmental determinants of cancer in minorities. Her work has a special focus on the role of physical activity as a key preventive behavior.
Dr. McNeill co-directs the Center for Community, Implementation, and Dissemination Research (CCIDR) at MD Anderson. CCIDR strives to change real-world public health and clinical practice through community-based research, implementation research and dissemination research.
She earned a Ph.D. in public health studies from Saint Louis University and a master's in health behavior and health education from the University of North Carolina at Chapel Hill. Prior to her appointment at MD Anderson, she was a postdoctoral fellow at the Harvard School of Public Health.
Bo Peng, Ph.D., is an instructor at the Department of Epidemiology. With a background in applied mathematics, biostatistics and bioinformatics, he is interested in numerical analysis, parallel computation, bioinformatics and population genetics.
During his research on the evolution of genetic diseases, Dr. Peng designed and implemented large-scale individual-based population genetics simulations. He applies these techniques to research in genetic epidemiology and public health genomics. Dr. Tsai is using a combination of mouse models and human tissue to explore the interactions of tumor cells and immune cell subsets relevant for tumor progression and tumor killing in cutaneous squamous cell carcinoma. He is also employing a cross-species genomic approach to identify genetic events that dictate the progression from actinic keratosis to squamous cell carcinoma. Recently his group has identified clinically relevant off-target effects of the BRAF inhibitors used for melanoma and is exploring these pathways in melanoma resistance. Dr. Tsai is also engaged in research exploring the identification and use of skin biomarkers to monitor and predict responses to targeted cancer therapies. He is a founding and steering committee member of the International Cognition and Cancer Task Force, which seeks to advance our understanding of the impact of cancer and cancer treatment on cognitive and behavioral functioning in adults with non-CNS cancers. He is also a member of the Response Assessment in NeuroOncology task force to define clinical trial endpoints in glioma.
He obtained his doctoral degree from the University of Houston, completed his internship at The University of Chicago Medical Center and his fellowship at MD Anderson Cancer Center.
Chongjuan Wei, Ph.D., is an assistant professor in the Department of Epidemiology. Dr. Wei's research involves Peutz-Jeghers Syndrome (PJS), an autosomal dominant disorder characterized by gastrointestinal hamartomatous polyps. People with PJS have dramatically increased risk for several cancers. Hyperactivation of mTOR has been associated with PJS, and Dr. Wei's work for the first time demonstrated that rapamycin, an mTOR inhibitory drug, effectively suppresses PJS polyposis. These preclinical studies on mouse models represent a new targeted therapy for prevention and treatment of PJS and PJS-associated cancer. He is a passionate advocate for education and has won the Leading Mentor in Cancer Prevention and Robert M. Chamberlain Outstanding Mentor awards. He has a variety of leadership responsibilities at MD Anderson, including membership on the Executive Committee for the Duncan Family Institute, and he has an extensive NIH-funded grant portfolio and more than 100 peer-reviewed publications. Xiangwei Wu, Ph.D., is an associate professor in the Department of Clinical Cancer Prevention. Dr. Wu has been studying mechanisms of apoptosis, specifically the death receptor pathways, for many years. He has made numerous important contributions in the area and his accomplishments were highlighted by publications in high profile journals. In the last few years, he started a translational research program to explore the application of death receptor pathways, such as TRAIL signaling, in cancer chemoprevention. In a scientific proof-of-concept study, he demonstrated that a twodrug combination, TRAIL and retinoid, destroys precancerous colon polyps without harming normal tissue, opening a new avenue for chemoprevention of colon cancer.
Dr. Wu has served on various committees and study sections. He has trained graduate students and postdoctoral fellows. He served on editorial board of scientific journals and reviewed papers for various journals. Dr. Wu has created an integrative research program that is visionary in concept and revolutionary in approach. She is a highly productive cancer epidemiologist with more than 250 publications in highly acclaimed journals, the principal investigator of several NIH-funded epidemiological studies and a major collaborator on many other projects. Dr. Wu supervises a 40-member research team and serves as mentor or advisor for several junior faculty, trainees and fellows, many of whom have won prestigious awards. She herself has received numerous awards from inside and outside the institution. She chairs the International Bladder Cancer Consortium. Ms. Tektiridis previously was administrative leader for the Cancer Center Support Grant, which funds 19 research programs and 24 core laboratory resources. This grant was renewed with a 15 percent increase, for a five-year total of more than $52.7 million, following an "Outstanding" peer review rating. She was recognized as a Rogers Award nominee.
Ms. Tektiridis has a bachelor's degree in Geology and Spanish and a master's degree in Management from Dickinson College in Pennsylvania. She is a certified public accountant and is enrolled in the Ph.D. in Health Management program at the UT School of Public Health. Prior to joining MD Anderson, she held various executive leadership positions.
